Year: 2024
Type: report
Abstract: eview question / Objective To compare the efficacy and treatment-related adverse events of antibody-drug conjugates in breast cancer. Condition being studiedPatients with breast cancer treated with antibody-drug conjugates in RCTs. METHODSParticipant or population Breast cancer patients, no matter molecular subtypes, disease stage, etc. Intervention Antibody-drug conjugates.Comparator Chemotherapy or physicians' choice. Study designs to be included RCTs.Eligibility criteria Breast cancer diagnosed with histology.
Authors: Yiqun Han, Meng Welliver, Robert Mutter
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4404026375